Intact Investment Management Inc. Purchases 2,520 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Intact Investment Management Inc. raised its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 79.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,700 shares of the medical research company’s stock after buying an additional 2,520 shares during the quarter. Intact Investment Management Inc.’s holdings in IQVIA were worth $1,120,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in IQV. Aviso Financial Inc. grew its holdings in shares of IQVIA by 3.4% during the fourth quarter. Aviso Financial Inc. now owns 129,467 shares of the medical research company’s stock worth $25,442,000 after purchasing an additional 4,222 shares in the last quarter. Atala Financial Inc bought a new position in shares of IQVIA in the 4th quarter worth $91,000. Commonwealth Equity Services LLC raised its position in shares of IQVIA by 0.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,104 shares of the medical research company’s stock valued at $5,130,000 after buying an additional 157 shares in the last quarter. Thompson Siegel & Walmsley LLC lifted its holdings in shares of IQVIA by 469.0% during the 4th quarter. Thompson Siegel & Walmsley LLC now owns 126,845 shares of the medical research company’s stock worth $24,926,000 after acquiring an additional 104,553 shares during the last quarter. Finally, Erste Asset Management GmbH grew its position in IQVIA by 0.4% in the fourth quarter. Erste Asset Management GmbH now owns 91,352 shares of the medical research company’s stock worth $18,095,000 after acquiring an additional 332 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IQV. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target for the company. Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Robert W. Baird cut their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Up 2.2 %

IQV opened at $185.40 on Friday. The stock has a market cap of $32.69 billion, a PE ratio of 24.72, a PEG ratio of 1.99 and a beta of 1.50. The business has a 50 day moving average of $196.63 and a 200-day moving average of $210.95. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $256.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.